𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma

✍ Scribed by Andrea Ardizzoni; Mara A. Cafferata; Michela Paganuzzi; Rosangela Filiberti; Paola Marroni; Monica Neri; Vincenzo Fontana; Guido Nicoló; Luisa Perdelli; Corrado Gallo Stampino; Riccardo Rosso; Riccardo Puntoni

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
102 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I clinical and pharmacologic stu
A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
✍ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 1 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist

Phase II study of pemetrexed disodium, a
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group
✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati